DBV Technologies reported $-61.2M in EBITDA for its fiscal quarter ending in September of 2026.





Ebitda Change Date
Acadia Pharmaceuticals USD 40.99M 42.62M Jun/2026
Alnylam Pharmaceuticals USD 360.27M 114.93M Sep/2026
Amarin USD 12.54M 28.57M Jun/2025
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
BioMarin Pharmaceutical USD 54.32M 167.99M Sep/2026
DBV Technologies USD -61.2M 15.3M Sep/2026
Galectin Therapeutics USD -7.42M 819K Dec/2021
Halozyme Therapeutics USD 336.16M 7.34M Sep/2026
Incyte USD 778.57M 410.6M Jun/2026
Insmed USD -80.97M 93.7M Sep/2026
Ionis Pharmaceuticals USD -95.22M 9.99M Sep/2026
Neurocrine Biosciences USD 375.3M 185.4M Sep/2026
PTC Therapeutics USD 161.9M 99.92M Jun/2026
Sarepta Therapeutics USD -3.14M 33.31M Sep/2026
Ultragenyx Pharmaceutical USD -61M 94M Jun/2026
United Therapeutics USD 334.2M 20.8M Sep/2026